Adult Dosing
Influenza A infection
Treatment
- 100 mg PO bid; start within 48 hrs of onset and discontinue within 24-48 hrs of symptom resolution
- 100 mg PO Daily in the elderly to avoid CNS effects; reduce dosage in debilitated patients
Prophylaxis
- 100 mg PO bid prior to or immediately upon exposure. 100 mg/day is recommended for patients intolerant to 200 mg/day
- 100 mg PO Daily in the elderly; reduce dosage in debilitated patients
- Continue for at least 10 days after known exposure
Parkinsonism
- Start: 100 mg PO bid for debilitated patients or for patients receiving other Parkinson disease treatment
- Max: 400 mg/day divided tid-qid
Drug-induced extrapyramidal disorders
- 100 mg PO bid. [Max: 300 mg/day divided tid-qid]
Neuroleptic malignant syndrome [Non FDA approved]
Pediatric Dosing
Influenza A infection
Treatment
- 1-9 yrs
- 4.4 to 8.8 mg/kg/day PO divided bid
- Max: 150 mg/day
- Start within 48 hrs of onset and discontinue within 24-48 hrs of symptom resolution
10 yrs- 100 mg PO bid
- Max: 200 mg/day
- Start within 48 hrs of onset and discontinue within 24-48 hrs of symptom resolution
Prophylaxis
- 1-9 yrs
- 4.4 to 8.8 mg/kg/day PO divided bid
- Max: 150 mg/day
- Start prior to or immediately upon exposure
- 10 yrs
- 100 mg PO bid
- Max: 200 mg/day
- Start prior to or immediately upon exposure
[Outline]
- Overdose of drug may result in cardiac, respiratory, renal or central nervous system toxicity. Deaths have been reported from overdose
- Suicide attempts, some of which have been fatal, have been reported in patients treated with amanatdine. Therapy can exacerbate mental problems in patients with a history of psychiatric disorders or substance abuse
- Closely monitor patients with a history of epilepsy or other seizures for possible increased seizure activity
- If central nervous system effects or blurring of vision occur caution advised against driving or working in situations where alertness and adequate motor coordination are important
- Closely monitor patients with a history of congestive heart failure or peripheral edema as therapy may develop congestive heart failure
- Do not use in patients with untreated angle-closure glaucoma as therapy has anticholinergic effects and may cause mydriasis
- Avoid abrupt withdrawal of therapy in Parkinson's disease as a sudden marked clinical deterioration may occur. Abrupt discontinuation may also precipitate delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression and slurred speech
- Closely monitor patients when drug is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics as Neuroleptic Malignant Syndrome (NMS) have been reported in association with dose reduction or withdrawal
Cautions: Use cautiously in
- live attenuated vaccine within 2 weeks before or 48 hours after administration
- Impaired impulse control patients
- Melanoma patients
- Hx of recurrent eczematoid rash
- Orthostatic hypotension
- Renal impairment
- Hepatic impairment
- Hx of psychiatric disorder
- Depression
- CV disease
- CHF
- Edema
- Angle closure glaucoma
- Seizure disorder
- Geriatric population
Pregnancy Category:C
Breastfeeding: Unsafe, avoid use due to negative effects on lactation. This information is based upon based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 16 February 2011). According to manufacturer's data use is not recommended in nursing mothers.
Pricing data from www.DrugStore.com in U.S.A.
- Amantadine HCl 100 MG TABS [Bottle] (UPSHER-SMITH)
30 mg = $52.99
90 mg = $148.47 - Amantadine HCl 50 MG/5ML SYRP [Bottle] (HI-TECH)
120 5ml = $15.99
360 5ml = $43.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
